This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Thomas P. Gibson, MD
Ortho-McNeil Pharmaceutical Raritan, NJ

JAMA. 1994;272(16):1252-1253.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Spielberg suggests that the company's "Dear Doctor" letter of April 9, 1982, describing reports of anaphylactic reactions to zomepirac was inadequate because it stated that those reactions were similar to those reported in association with the use of other nonsteroidal anti-inflammatory drugs.

After the marketing of zomepirac in 1980, reports of adverse experiences resembling anaphylactic reactions were reported to Ortho-McNeil Pharmaceutical. A number of those reports occurred in aspirin-sensitive patients for whom zomepirac and other nonsteroidal anti-inflammatory drugs are contraindicated. These were promptly reported to the FDA. In close collaboration with the FDA, the company drafted and issued the Dear Doctor letter to draw attention to these reactions and provide additional information to physicians so that zomepirac could be properly prescribed.

Advertising campaigns with appropriate fair balance have always been acceptable forms of promotion for approved and marketed medications. However, because of continued reports of anaphylactic reactions, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?